for a company with $2 in cash
2 patents out to 2025 in US AND Europe
FDA recognized/designation for Biodel glucagon as orphan drug treatment of choice for congenital hyperinsulinemia
an actual pipeline.
Yes you can wait for another 2 years...by this time there will be 3 phase three studies...biod 123, biod 250, and biod 500. Glucagon's NDA should already be filed by 2015.
Sure BIOD will be a lot more by then...5 will be cheap. if BIOD executes